A case report of immune-related multisystem adverse reactions caused by tislelizumab
10.12173/j.issn.1005-0698.202311030
- VernacularTitle:替雷利珠单抗致免疫相关性多系统不良反应1例
- Author:
Qiuyan SONG
1
;
Qirui TAI
;
Bikui ZHANG
;
Zhiying LUO
;
Bao SUN
;
Wenhui LIU
Author Information
1. 玉溪市人民医院药学部(云南 玉溪 653100)
- Publication Type:Journal Article
- Keywords:
Tislelizumab;
Myasthenia gravis;
Myositis;
Myocarditis;
Liver function damage;
Immune-related adverse reaction
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(3):359-364
- CountryChina
- Language:Chinese
-
Abstract:
A 35-year-old female patient with advanced lung cancer was treated with paclitaxel(albumin-bound)and carboplatin chemotherapy,combined with tislelizumab immunotherapy for one cycle.After 6 days of treatment,the patient developed sagging of the right eyelid compared to the leftside,mild morning and heavy evening,systemic muscle soreness,abnormal transaminases and myocardial enzymes,and abnormal electrocardiogram.It is suspected that there may be a correlation between tislelizumab and myasthenia gravis or related myositis.After admission,patients were treated with methylprednisolone,intravenous immunoglobulin,plasma exchange,mycophenolate mofetil,temporary pacemaker installation,and tracheal intubation.After more than a month of treatment,the patient's indicators decreased,but the patient became unconscious,the patient's family requested discharge.The association between the multisystem adverse reactions and tislelizumab was evaluated using the Naranjo's Assessment Scale,the correlation score was 7 and evaluated as probably relevant.It is suggested that when using tislelizumab in clinical practice,risk factor assessment and medication monitoring should be strengthened to ensure drug safety.
